Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study.

To assess the noninferiority, efficacy, and safety of degarelix in achieving and maintaining testosterone at castrate levels (≤0.5 ng/mL) in Korean patients (CS42) versus non-Asian patients with prostate cancer (PCa).

A Phase III, open-label, multicenter, single-arm trial was conducted in Korean patients with PCa Degarelix was administered at a starting dose of 240 mg followed by monthly (28-day intervals) maintenance doses of 80 mg (240/80 mg dose regimen) for 7 months The results were compared with non-Asian patients receiving degarelix 240/80 mg in the CS21 study

The estimated difference in the cumulative probabilities of testosterone ≤0 5 ng/mL from Day 28 to Day 196 between the trials was -2 3% (96 7% in CS42 vs 99 0% in CS21) The lower limit of the 95% confidence interval was -5 5%, i e , above the predefined noninferiority limit of -10% and thus noninferiority was established Decreases in serum testosterone, prostate-specific antigen, and luteinizing hormone over time were similar in CS42 and CS21 There were no clinically significant differences in incidence of treatment-emergent adverse events (72% in CS42 vs 70% in CS21) and changes in clinical chemistry and hematology parameters between the two trials The most common adverse event was injection-site reaction

Overall, degarelix was effective and well tolerated in Korean patients Testosterone suppression was noninferior to that in non-Asian patients and safety findings were as would be expected for elderly men with PCa undergoing androgen deprivation therapy

Prostate international 2015 Feb 12 [Epub]

Dalsan You, Byung Ha Chung, Sang Eun Lee, Choung-Soo Kim

Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea , Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, South Korea , Department of Urology, Seoul National University Bundang Hospital, Seongnam, South Korea , Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

PubMed     Full Text Article

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe